Skip to main content
Living With CMT2CHome

For professionals

CMT2C for clinicians: a summary for each specialty

CMT2C is rare, so most clinicians meet it once or twice in a career. This page gathers, for each specialty, what the published sources say: what the condition is, what is usually checked, the known cautions, and the papers behind each point. None of it is my own words: a patient brought the experts’ words together, as a starting point, not a guideline. Choose your specialty below to see only that section, with its papers and why each one is relevant.

At a glance

CMT2C is an autosomal dominant axonal neuropathy caused by gain-of-function variants in TRPV4, a calcium-permeable ion channel [10]. Unlike most forms of CMT, it often involves the vocal folds and the diaphragm, and it can affect hearing, the skeleton and the bladder [6]. Severity varies widely, even within one family, and cannot be predicted from the variant [6]. No treatment yet changes its course [5]; care is surveillance and symptom management by a multidisciplinary team, with checks once a year [6].

Where this comes from. I live with CMT2C and I am not a clinician. Nothing here is my own medical opinion: every point is the published experts’ words, cited beside it, mostly the GeneReviews chapter by McCray, Schindler, Hoover-Fong and Sumner [6] and the 2025 TRPV4 registry paper in Brain [3], brought together in one place so it is easier to digest and to check at its source. It is a consolidation, not a guideline. Where the site draws on literature about neuromuscular disease in general rather than CMT2C, it says so.

A one-page summary for any clinician

The key point: in CMT2C the weakness is not only in the feet and hands; the voice box and the breathing muscles are often involved, and the sources caution against oxygen alone or CPAP for weak breathing muscles.

What it is

  • Autosomal dominant axonal CMT caused by gain-of-function variants in TRPV4 [10]. Also written up as HMSN 2C, TRPV4 neuropathy, scapuloperoneal SMA (SPSMA) and congenital distal SMA (CDSMA), which are now treated as one overlapping spectrum [6].
  • Rare: Orphanet lists a prevalence under 1 in 1,000,000 [1]. TRPV4 explains an estimated 1 to 3.5% of CMT2 and related motor neuropathies [6].
  • Onset from birth to after 80, with two peaks: 54% of registry participants had symptoms within the first 2 years of life, and a smaller peak came at 34 to 48 years [3] [6].
  • Nerve conduction studies show reduced motor amplitudes with normal velocities; EMG shows mainly chronic neurogenic changes [6].

What is different from typical CMT

  • Vocal fold weakness is a hallmark: diagnosed in 55% of registry participants, and in 85% of those who had actually been examined by an ENT specialist [3]. Hoarseness 45%, inspiratory stridor 40% [3].
  • Diaphragm weakness: 55% short of breath, 23% on BiPAP, more than 10% have needed ventilatory support or a tracheostomy [3]. In severe forms, respiratory complications can shorten life [6].
  • Proximal weakness: 40% had proximal leg weakness on examination, against 4% in a CMT1A comparison group [3]. Shoulder girdle (scapular) weakness is part of the picture [6].
  • Skeleton: foot deformities 73%, scoliosis 39 to 64% depending on the data source, clubfoot 45%, arthrogryposis 33%, hip dysplasia 18% [3]. Some variants also cause a skeletal dysplasia [6].
  • Hearing loss in 27%, bladder symptoms in up to 45% [3]. Sensory symptoms are often absent (68% reported none) although vibration sense is reduced on examination in 84% [3].

Recommended surveillance (GeneReviews)

After diagnosis: video laryngoscopy, pulmonary function tests and dynamic chest radiographs, a sleep study, a hearing assessment and skeletal radiographs [6]. Then, once a year: voice box, breathing, sleep, hearing, feet and skeleton, with weight and height at each visit [6].

Cautions

  • Oxygen alone can be dangerous when breathing muscles are weak: guidance for other neuromuscular conditions warns that it can mask or worsen hypercapnia without ventilatory support [153]. The sources advise measuring carbon dioxide, not only saturation [126].
  • CPAP does not treat neuromuscular hypoventilation [307]. Weak breathing muscles need ventilation: bilevel support with a wide pressure gap and a backup rate, or a home ventilator [307] [308]. Some references still write “BiPAP or CPAP” together [6].
  • Anesthesia: vocal fold weakness and diaphragm weakness both matter. Reviews of anesthesia in neuromuscular disease call for a careful preoperative assessment, close monitoring and ventilatory support ready afterward [290].
  • Neurotoxic drugs: the CMTA's evidence-based list names vincristine (severe, sometimes irreversible worsening) and paclitaxel [35]. A 2023 systematic review found no convincing evidence against other drugs and stressed that people with CMT should not be denied effective treatments [36].
  • Upper respiratory infections cause vocal fold swelling and worsen airway obstruction; GeneReviews also advises avoiding obesity and diabetes [6].

Where to send people

The CMTA keeps a directory of CMT Centers of Excellence [85] and of clinicians with CMT experience [128]. Two natural history studies recruit people with TRPV4 variants: the Johns Hopkins TRPV4 study, NCT05600764 (United States and Canada) [101], and INC 6601, the Inherited Neuropathy Consortium's study for all CMT types, at 21 sites in five countries [52]. Details below.

Neurology

The key point: in a patient with axonal CMT, vocal cord paralysis, scapular weakness, a skeletal dysplasia or hearing loss are the published clues that point to TRPV4 testing [18].

What the literature describes

  • An axonal motor-predominant neuropathy: reduced motor amplitudes with normal conduction velocities, and chronic neurogenic changes on EMG [6]. Many patients report no sensory symptoms, yet vibration sense is reduced on examination in 84% [3].
  • Weakness that is not length-dependent: proximal leg weakness in 40% (4% in CMT1A) and scapular weakness, alongside the usual distal pattern [3] [6]. Wheelchair use was 19% against 1% in CMT1A [3].
  • Wide variability, including within one family, from arthrogryposis at birth to an asymptomatic 70-year-old carrier [6]. Age predicts severity less well than in CMT2A or CMTX1 [3].
  • Age of onset has two peaks, early childhood and the mid-thirties to late forties [3].

What the sources recommend

  • Genetic confirmation: sequence analysis detects essentially all pathogenic TRPV4 variants [6]. Variants of uncertain significance are common, and a 2025 study showed that separating pathogenic from benign TRPV4 variants takes combined clinical, structural and cellular evidence [22]. The site's TRPV4 variants page lists the well-documented ones.
  • The baseline work-up GeneReviews recommends: video laryngoscopy, pulmonary function tests with dynamic chest radiographs, a sleep study, audiology and skeletal radiographs, then yearly review [6]. Standard CMT care focused on the feet and hands is not enough for this subtype [6].
  • Coordination: GeneReviews describes care as multidisciplinary, across neurology, rehabilitation medicine, orthopedics, audiology, laryngology, pulmonology, and physical and occupational therapy [6]. From the patient side, the neuromuscular neurologist is usually the one who coordinates.
  • Research: both natural history studies need participants, and the registry authors call for outcome measures that capture non-length-dependent weakness, vocal fold weakness and respiratory involvement, which standard CMT scales miss [3]. How to refer.

Cautions

  • Vincristine and paclitaxel are the two drugs with evidence-backed potential for harm in CMT [35] [36].
  • In a progressive condition with no disease-modifying treatment [5], the first TRPV4-targeted drug, STAR-0871 (previously ABS-0871), has completed a Phase 1a study in healthy volunteers, and its developer plans a trial in people with CMT2C in 2027 [318] [319]. Patients may ask about it; the Trials and research page keeps the status current.

Papers that may help

  • Autosomal Dominant TRPV4-Related Disorders

    McCray et al. · 2014 · GeneReviews

    Full paperGeneReviews chapter, peer reviewed

    For this specialty: The standard clinical summary, including the surveillance schedule and management by problem.

    Relevance to CMT2C: A clinical overview written specifically about TRPV4 neuromuscular disease, with CMT2C as a named core phenotype.

  • TRPV4 neuromuscular disease registry highlights bulbar, skeletal and proximal limb manifestations

    Kosmanopoulos et al. · 2025 · Brain : a journal of neurology

    Full paperPeer-reviewed journal

    For this specialty: The registry that gives the bulbar, skeletal and proximal figures quoted in this section.

    Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.

  • Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C

    Landouré et al. · 2010 · Nature genetics

    Full paperPeer-reviewed journal

    For this specialty: One of the papers that first linked CMT2C to TRPV4.

    Relevance to CMT2C: One of the founding papers showing that TRPV4 changes cause CMT2C, with clinical details on affected family members.

  • Incidence and Clinical Features of TRPV4-Linked Axonal Neuropathies in a USA Cohort of Charcot-Marie-Tooth Disease Type 2

    Deng et al. · 2020 · Neuromolecular medicine

    Full paper (scan)Peer-reviewed journal

    For this specialty: The US cohort behind the clinical clues for TRPV4 testing: vocal cord paralysis, scapular weakness, skeletal dysplasia or hearing loss.

    Relevance to CMT2C: Describes people with TRPV4-related CMT2C, including voice, breathing and hearing problems and variation within a family, and estimates how often TRPV4 explains CMT2 in a USA clinic cohort.

  • Reduced penetrance in hereditary motor neuropathy caused by TRPV4 Arg269Cys mutation

    Berciano et al. · 2011 · Journal of neurology

    Full paper (scan)Peer-reviewed journal

    For this specialty: Reduced penetrance in one family, from a severely affected child to a relative with no findings at 70.

    Relevance to CMT2C: A detailed study of a family with a TRPV4 ankyrin-region change (Arg269Cys) that directly addresses penetrance and variability, which matter to people with CMT2C and their relatives.

  • Combined clinical, structural and cellular studies discriminate pathogenic and benign TRPV4 variants

    Berth et al. · 2025 · Brain : a journal of neurology

    Full paperPeer-reviewed journal

    For this specialty: How pathogenic and benign TRPV4 variants were told apart with combined clinical, structural and cellular evidence.

    Relevance to CMT2C: It directly addresses how to tell disease-causing from harmless TRPV4 variants in neuropathy, which matters for anyone given an uncertain TRPV4 result, but most of the work is in lab cells rather than patients.

  • Comprehensive analysis of the TRPV4 gene in a large series of inherited neuropathies and controls

    Fawcett et al. · 2012 · Journal of neurology, neurosurgery, and psychiatry

    Full paperPeer-reviewed journal

    For this specialty: TRPV4 screened in a large series of inherited neuropathies, with the features that went with a positive result.

    Relevance to CMT2C: It measures how often TRPV4 changes cause axonal CMT and motor neuropathy and shows that many rare TRPV4 variants are harmless, which matters for anyone given a TRPV4 result, though no confirmed CMT2C cases were found.

All 271 papers the site has read are on Papers explained, each with what was read (full text, detailed notes or abstract only) and what its evidence rests on.

Pulmonology and sleep medicine

The key point: in the neuromuscular literature, hypoventilation from a weak diaphragm is treated with ventilation (bilevel or a ventilator); CPAP and oxygen alone are cautioned against [307] [153].

What the literature describes

  • Diaphragm weakness is part of the disease [6]. In the registry, 55% were short of breath, 23% used BiPAP, 10% used CPAP, and more than 10% had needed ventilatory support or a tracheostomy [3].
  • Vocal fold weakness in most patients [3], so inspiratory stridor (40%) and upper airway obstruction coexist with the muscle weakness [3] [6]. Orthopnea and sleep apnea can occur [6].
  • Symptoms start at night: orthopnea or anxiety lying flat, fragmented sleep, unrefreshing sleep, morning headache, repeated chest infections, daytime sleepiness [288] [289].

What the sources recommend

These points come from a specialist's review of respiratory management in neuromuscular disease in general [288]; none has been studied in CMT2C specifically.

  • Vital capacity sitting and supine. A fall of more than 7.5% on lying down points to diaphragm weakness, often before upright values change [288]. GeneReviews lists dynamic chest radiographs alongside pulmonary function tests [6].
  • Nocturnal carbon dioxide, not only oximetry: standard sleep studies are built for apnea and can score hypoventilation as apneas [288].
  • Cough peak flow; about 160 liters a minute is the minimum for an effective cough [288]. For a weak cough: air stacking and mechanical insufflation-exsufflation, set up while the patient is well [288].
  • If ventilation is needed: bilevel support with a wide gap between inspiratory and expiratory pressures, a backup rate, or volume-assured modes [307] [311]. The 2023 CHEST guideline recommends non-invasive ventilation for chronic respiratory failure in neuromuscular disease [308].
  • Yearly review of breathing and sleep, as GeneReviews recommends [6].

Cautions

  • “Continuous positive-airway pressure (CPAP) is not adequate to treat hypoventilation that occurs with NMD” [307]. Some patients are still told to fail CPAP first [312]. CPAP has a place only for obstructive sleep apnea confirmed by testing in a patient whose breathing muscles are strong [288].
  • Oxygen without ventilatory support can mask or worsen hypercapnia [153].
  • Colds are the usual trigger for respiratory crises, when a weak cough cannot clear secretions [288]. A plan for infections, agreed in advance, is something patients often ask for.

Papers that may help

The patient-facing version of this page is Breathing and voice, with a printable handout on morning headaches.

ENT, laryngology and speech therapy

The key point: vocal fold paresis is a hallmark of TRPV4 disease [6], and it is usually missed until someone looks: 85% of registry participants examined by an ENT specialist had it, against 55% diagnosed overall [3].

What the literature describes

  • Vocal fold weakness or paralysis, hoarseness (45%) and inspiratory stridor (40%) [3]. In the first description of the disease, it was the combination of distal weakness with vocal cord and diaphragm paresis that defined it [6].
  • Across all CMT types, a 2001 review found only 11 published cases of vocal fold paresis and said many had probably been missed [313]. In TRPV4 disease it is the rule rather than the exception [3].
  • Within one family the same variant ranged from no vocal fold problem to a permanent tracheotomy (Chen et al., 2010).

What the sources recommend

  • Video laryngoscopy at diagnosis and a yearly voice box review, as GeneReviews recommends [6].
  • Management as listed by GeneReviews: speech therapy, laryngeal surgery when needed, vocal fold lateralization to widen the airway in selected patients, and tracheostomy for some [6].
  • Swallowing: the registry grouped voice, swallowing and breathing as bulbar manifestations [3]; patients value a swallowing assessment when they report choking or a weak cough.
  • Hearing is often affected in the same patients (27%) [3]; see Audiology.

Cautions

  • Upper respiratory infections cause vocal fold swelling and can worsen airway obstruction [6].
  • Before any procedure under sedation or anesthesia, the airway and the diaphragm both need planning; see Anesthesiology.

Papers that may help

Anesthesiology and surgical teams

The key point: vocal fold and diaphragm weakness are both common and often undiagnosed; reviews of anesthesia in neuromuscular disease recommend a careful preoperative assessment and ventilatory support ready afterward [290].

What the literature describes

  • Vocal fold paresis in most patients, often undiagnosed [3], and diaphragm weakness that may show only when supine [288].
  • Patients who cannot lie flat comfortably, and some who already use nocturnal bilevel ventilation (23% in the registry) [3].
  • Orthopedic surgery is common in this group: 49% had had foot surgery [3], and spinal fusion is considered for scoliosis with pain or respiratory compromise [6].

What the sources recommend

The site has no CMT2C-specific anesthesia literature. These points are what reviews of anesthesia in neuromuscular disease, collected by the patient charity Breathe with MD, consistently say [290].

  • A careful preoperative respiratory assessment, including vital capacity supine as well as sitting [288], and knowledge of the patient's laryngoscopy findings.
  • Close monitoring during and after the procedure, including carbon dioxide [126].
  • Noninvasive ventilation available for recovery, and the patient's own bilevel settings if they use one [290] [307].
  • Many patients carry a summary of their breathing results and know their own stridor and swallowing history.

Cautions

  • Supplemental oxygen without ventilatory support can mask or worsen hypercapnia in neuromuscular weakness [153].
  • CPAP does not treat hypoventilation from weak muscles [307].
  • Postoperative respiratory infections carry extra risk when the cough is weak [288].
  • One 2026 case report describes severe noninfectious wound dehiscence after cavovarus reconstruction in a child with TRPV4-associated CMT; a single case cannot show a general healing problem, but the authors raise the question (Elhaddad et al., 2026).

Papers that may help

Orthopedics and orthotics

The key point: the skeleton is involved beyond the usual cavus foot; the sources describe hip and spine involvement, and breathing is relevant before any long operation.

What the literature describes

  • Foot deformities in 73%, foot surgery in 49%, clubfoot in 45%, arthrogryposis in 33% [3].
  • Scoliosis in 64% of questionnaire respondents and 39% of registry records [3]. Hip dysplasia in 18% [3]; in one Australian pediatric cohort, all four children with TRPV4-related CMT had hip dysplasia on X-ray and two needed hip surgery (Tan et al., 2025).
  • Some TRPV4 variants also cause skeletal dysplasias, and mixed neuropathy and skeletal phenotypes exist [6] (Taga et al., 2022). Short stature is reported in some families (Chen et al., 2010).
  • Proximal weakness (40%) and arthritic-like pain (49%) [3].

What the sources recommend

  • Skeletal radiographs at diagnosis and a yearly review of feet and skeleton [6]. Hip imaging in children may be worth considering (Tan et al., 2025).
  • Standard care as GeneReviews lists it: supportive footwear, orthotics, ankle-foot or knee-ankle-foot orthoses; daily heel cord stretching; surgery for severe cavus or contractures; orthopedic evaluation of scoliosis, with spinal fusion considered when there is pain or pulmonary compromise [6].
  • Custom braces in plastic or carbon fiber, and boots or high-top shoes for ankle stability [83].

Cautions

  • Before surgery, the breathing and the vocal folds need an anesthesia plan; see Anesthesiology.
  • A 2026 single case of severe noninfectious wound dehiscence after cavovarus reconstruction in TRPV4-associated CMT raises a question about healing that only more cases can answer (Elhaddad et al., 2026).
  • Some patients are short of breath on exertion or cannot lie flat for imaging.

Papers that may help

Physical and occupational therapy

The key point: moderate resistance and balance training appear safe and helpful in CMT, very high-intensity training is discouraged [56], and in this subtype the hips, shoulders and breathing matter as much as the feet.

What the literature describes

  • Difficulty walking (79%) and with balance (79%), orthotic use (49%), at least intermittent wheelchair use (32%) [3].
  • Proximal leg weakness in 40% and scapular weakness, so sit-to-stand, stairs and overhead tasks are affected, not only foot clearance [3] [6].
  • Hands: 49% struggle with buttons or zippers and 23% with eating utensils [3].
  • Contractures and tight heel cords, sometimes from birth [3] [6].

What the sources recommend

  • GeneReviews: daily stretching of tight heel cords, balance work, moderate strengthening and advice on orthoses [6].
  • A home program the person can keep up; a systematic review of exercise in CMT (7 studies, 170 patients) found moderate resistance and balance training safe and helpful [56].
  • Occupational therapy for the hands: adaptive tools such as button hooks, weighted utensils and jar openers, and splints where useful [152].
  • Patients are often told to find a therapist who knows neuromuscular disease [65]; they may ask whether you have treated CMT before [127].

Cautions

  • Breathlessness during exercise or when lying down may be diaphragm weakness rather than deconditioning [288]; a referral back may be worth considering.
  • Very high-intensity training is discouraged in CMT [56].

Papers that may help

The patient-facing Movement guide has the self-checks and the illustrated exercises your patient may bring to you.

Audiology

The key point: hearing loss in TRPV4 disease can be an auditory neuropathy. In one child, speech perception in noise worsened over three years while the standard audiogram stayed stable (Rance et al., 2024).

What the literature describes

  • Partial hearing loss in 27% of registry participants [3]. Hearing loss was among the features in the first TRPV4 papers (Landouré et al., 2010).
  • In one family with the R269H variant, everyone with the variant developed hearing loss from the inner ear or the hearing nerve, usually noticed in mid-life (Oonk et al., 2014).

What the sources recommend

  • A hearing assessment at diagnosis and once a year, with rehabilitation options when loss is found [6].
  • Tests of speech perception in noise and auditory nerve function, not only pure-tone thresholds, may be worth considering given the case above (Rance et al., 2024).
  • In someone with hearing loss and an axonal neuropathy, TRPV4 is one of the genes to think of [18].

Papers that may help

  • Remediation of Perceptual Deficits in Progressive Auditory Neuropathy: A Case Study

    Rance et al. · 2024 · Journal of clinical medicine

    For this specialty: Progressive auditory neuropathy in one child with a TRPV4 variant, with a stable audiogram, and how it was managed.

  • Intrafamilial variable hearing loss in TRPV4 induced spinal muscular atrophy

    Oonk et al. · 2014 · The Annals of otology, rhinology, and laryngology

    Detailed summary onlyPeer-reviewed journal

    For this specialty: Variable hearing loss within one TRPV4 family, usually noticed in mid-life.

    Relevance to CMT2C: It is a detailed hearing study in a TRPV4 neuromuscular family carrying R269H, which the summary notes is one of the common CMT2C mutations, though the family's own diagnosis is spinal muscular atrophy rather than CMT2C.

  • Hearing loss in inherited peripheral neuropathies: Molecular diagnosis by NGS in a French series

    Lerat et al. · 2019 · Molecular genetics & genomic medicine

    Full paperPeer-reviewed journal

    For this specialty: Hearing loss in inherited neuropathies, with one TRPV4 case of auditory neuropathy and weak vocal cords.

    Relevance to CMT2C: Mostly about other neuropathy genes, but includes one TRPV4 patient with auditory neuropathy and vocal cord paresis and a note on recorded hearing loss among five TRPV4 patients.

  • Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C

    Landouré et al. · 2010 · Nature genetics

    Full paperPeer-reviewed journal

    For this specialty: Hearing loss among the features in one of the first TRPV4 papers.

    Relevance to CMT2C: One of the founding papers showing that TRPV4 changes cause CMT2C, with clinical details on affected family members.

  • TRPV4 neuromuscular disease registry highlights bulbar, skeletal and proximal limb manifestations

    Kosmanopoulos et al. · 2025 · Brain : a journal of neurology

    Full paperPeer-reviewed journal

    For this specialty: The registry figure for partial hearing loss.

    Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.

Genetics and genetic counseling

The key point: penetrance is reduced and expressivity is extreme, so the same variant can mean arthrogryposis in one relative and nothing on examination in another [6].

What the literature describes

  • Autosomal dominant inheritance; de novo variants and somatic mosaicism are both reported [6] (Lee et al., 2025).
  • Reduced penetrance: a 70-year-old carrier with no detectable signs in one family (Berciano et al., 2011). How often carriers stay unaffected for life is unknown; the site tracks how each paper decided a relative was unaffected, because that is what penetrance estimates rest on.
  • One gene, several diagnoses: CMT2C, SPSMA and CDSMA are allelic and now described as one spectrum [6], and other TRPV4 variants cause skeletal dysplasias [6].
  • Variants of uncertain significance are common in TRPV4. Distinguishing pathogenic from benign variants took combined clinical, structural and cellular evidence in a 2025 study [22].

What the sources recommend

  • Sequence analysis detects essentially all pathogenic variants [6]. The site's TRPV4 variants page lists the well-documented neuromuscular variants and explains classifications to patients.
  • Genetic counseling for the family [6]. In pregnancy, a high-risk obstetrician or maternal-fetal medicine specialist is advised [6].
  • Reproductive options, including IVF with preimplantation genetic testing, are set out for patients on Practical tips in a deliberately non-directive way, following the ASRM's approach.
  • Research: a confirmed variant is the entry ticket to the natural history studies [101] [52]; see Referral and research.

Papers that may help

Pediatrics

The key point: more than half of registry participants had symptoms in the first two years of life [3]. Clubfoot, arthrogryposis, stridor or a weak cry in a baby with hypotonia can be CMT2C.

What the literature describes

  • Congenital presentations: clubfoot (45%), arthrogryposis (33%), and the congenital distal SMA end of the spectrum [3] [6]. One family's report describes an infant who needed a breathing tube from early life while a sibling had almost no signs (Aharoni et al., 2011).
  • Vocal fold weakness with stridor, and respiratory weakness, in childhood as well as later [6].
  • Hip dysplasia: all four TRPV4 children in one large pediatric CMT cohort had it (Tan et al., 2025). Scoliosis and short stature in some [3] (Chen et al., 2010).
  • Hearing: a progressive auditory neuropathy was documented in one child despite a stable audiogram (Rance et al., 2024).

What the sources recommend

  • The GeneReviews baseline (laryngoscopy, lung function, sleep study, hearing, skeletal radiographs) and yearly review, with height and weight at every visit [6].
  • Hip imaging and spine surveillance (Tan et al., 2025) [6].
  • Early physical therapy for contractures and heel cords [6], and genetic counseling for the family [6].
  • The Johns Hopkins natural history study enrolls from age 3 [101].

Cautions

  • Respiratory infections, anesthesia and oxygen carry the same cautions as in adults; see Pulmonology and Anesthesiology.
  • Severity in a child does not predict the course: one newborn who was very ill improved over the following years while his father stayed stable for two decades (Vill et al., 2015).

Papers that may help

Primary care and emergency departments

The key point: chest infections carry extra risk when the cough is too weak to clear secretions; the sources caution that oxygen alone can hide rising carbon dioxide and that CPAP does not treat weak breathing muscles [288] [153] [307].

In an emergency

  • The patient usually knows about their breathing-muscle weakness, nocturnal ventilation and vocal fold weakness, so it is worth asking [3].
  • Carbon dioxide, not only saturation, is the measurement the sources ask for [126]. If oxygen is needed, the sources advise giving it with ventilatory support rather than alone [153].
  • Noisy breathing, a sudden change in voice or swallowing, or increasing breathlessness need urgent assessment [6].
  • Clearing secretions: air stacking or mechanical insufflation-exsufflation if available [288].

In the office

  • The yearly checks in GeneReviews are voice box, breathing, sleep, hearing, feet and skeleton [6]. The care team guide on this site is the patient's checklist for them.
  • Sleep is worth a question: orthopnea, unrefreshing sleep and morning headache are early signs of nocturnal hypoventilation [288] [289].
  • Prescribing: vincristine and paclitaxel are the two drugs to avoid; other drugs have no convincing evidence of harm, and effective treatment should not be withheld [35] [36].
  • Weight, diabetes and respiratory infections are the things GeneReviews says to avoid or treat early [6].
  • Bladder symptoms (45% difficulty urinating, 26% incontinence) and pain (49% arthritic-like) are common and rarely asked about [3]. So is low mood; the site has a page for both.
  • Referral to a neuromuscular neurologist or a CMT Center of Excellence is the usual next step [85].

Papers that may help

Referral, research and contact

  • Specialist care. The CMTA's directories of Centers of Excellence [85] and of clinicians with CMT experience [128]. The site's Standard care page lists the centers.
  • Natural history studies. Johns Hopkins, NCT05600764: ages 3 to 80 with a TRPV4 variant, United States and Canada, one visit a year for six years, travel reimbursed [101]. INC 6601: any CMT type, 21 sites in the US, Canada, the UK, Italy and Australia [52]. The 2025 registry paper was built from INC data [3].
  • Treatment pipeline. STAR-0871 (previously ABS-0871) is an oral TRPV4 inhibitor with FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations; a Phase 1b study in people with CMT2C is planned for 2027 [318] [319]. The Trials and research page follows every candidate.
  • The literature. Papers explained analyzes 106 papers in detail and lists 271 in all, each labeled by how it was read and what its evidence rests on. How the papers were analyzed explains the method.
  • Corrections. If something on this page is wrong or out of date, please tell me: cmt2cinfo@gmail.com. Clinicians' corrections have already shaped this site, and I will credit you if you wish.

This page brings together published expert sources for education; it is not medical advice or a clinical guideline. Every statement is referenced to the numbered sources. Last reviewed October 2026.

Next: For researchers